Dynavax Technologies Gross Profit 2010-2022 | DVAX
Dynavax Technologies gross profit from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Dynavax Technologies Annual Gross Profit
(Millions of US $) |
| 2021 |
$266 |
| 2020 |
$35 |
| 2019 |
$25 |
| 2018 |
$-3 |
| 2017 |
$0 |
| 2016 |
$11 |
| 2015 |
$4 |
| 2014 |
$11 |
| 2013 |
$11 |
| 2012 |
$10 |
| 2011 |
$22 |
| 2010 |
$24 |
| 2009 |
$40 |
Dynavax Technologies Quarterly Gross Profit
(Millions of US $) |
| 2022-03-31 |
$74 |
| 2021-12-31 |
$121 |
| 2021-09-30 |
$48 |
| 2021-06-30 |
$38 |
| 2021-03-31 |
$59 |
| 2020-12-31 |
$15 |
| 2020-09-30 |
$9 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$9 |
| 2019-12-31 |
$8 |
| 2019-09-30 |
$7 |
| 2019-06-30 |
$6 |
| 2019-03-31 |
$4 |
| 2018-12-31 |
$4 |
| 2018-09-30 |
$-2 |
| 2018-06-30 |
$-4 |
| 2018-03-31 |
$-0 |
| 2017-12-31 |
$0 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$7 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$3 |
| 2016-03-31 |
$1 |
| 2015-12-31 |
$1 |
| 2015-09-30 |
$1 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$2 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$3 |
| 2013-12-31 |
$3 |
| 2013-09-30 |
$3 |
| 2013-06-30 |
$3 |
| 2013-03-31 |
$2 |
| 2012-12-31 |
$2 |
| 2012-09-30 |
$3 |
| 2012-06-30 |
$3 |
| 2012-03-31 |
$2 |
| 2011-12-31 |
$11 |
| 2011-09-30 |
$1 |
| 2011-06-30 |
$7 |
| 2011-03-31 |
$2 |
| 2010-12-31 |
$2 |
| 2010-09-30 |
$12 |
| 2010-06-30 |
$2 |
| 2010-03-31 |
$8 |
| 2009-12-31 |
$2 |
| 2009-09-30 |
$3 |
| 2009-06-30 |
$16 |
| 2009-03-31 |
$19 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.441B |
$0.439B |
|
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
|
